Although mergers and acquisitions have slowed down in the home infusion market, it’s good news for owners. Valuations in the sector are strong because of a shortage in inventory. Managing Director Reg Blackburn gave insight to HME News.
“There are fewer new startups, and the other guys have been consolidating. It’s definitely a supply and demand issue. The biggest driver is IVIg therapy, so you do see specialty pharmacy players starting IVIg programs and seeing a better gross profit there.”
– Reg Blackburn